Therefore, in NSCLC with EGFR mutations, EGFR-TKIs and anti-PD-1 antibodies may have similar but not synergistic effects in disrupting the PD-1/PD-L1 interaction (71). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.